🇺🇸 FDA
Patent

US 11725207

Serpina1 iRNA compositions and methods of use thereof

granted A61PA61P1/16A61P35/00

Quick answer

US patent 11725207 (Serpina1 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
123
CPC classes
A61P, A61P1/16, A61P35/00, A61P43/00